Why Dexpramipexole

Our Rationale for Investigating Dexpramipexole in Eosinophilic Asthma

Scroll to discover
Why Dexpramipexole


Knopp’s Development Candidate for Eosinophilic Asthma

Dexpramipexole was discovered to profoundly deplete eosinophils, a type of inflammatory cell found in asthma and other diseases. In the last five years, three drugs that work by lowering eosinophils have been approved by the FDA for the treatment of asthma. These drugs require regular injections, while dexpramipexole is being developed as an oral medicine.

What happens during an Asthmatic Attack?

Our goal is to demonstrate the safety and effectiveness of oral dexpramipexole.

Knopp Biosciences

Meet the Team Behind Dexpramipexole